HCA HEALTHCARE INC (HCA) Forecast, Price Target & Analyst Ratings
NYSE:HCA • US40412C1018
532.81 USD
-1.66 (-0.31%)
At close: Mar 6, 2026
532.81 USD
0 (0%)
After Hours: 3/6/2026, 8:23:49 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HCA HEALTHCARE INC (HCA).
Forecast Snapshot
Consensus Price Target
$546.10
+ 2.49% Upside
Next Earnings Forecast
Release DateApr 23, 2026
PeriodQ1 / 2026
EPS Estimate$7.27
Revenue Estimate19.275B
ChartMill Buy Consensus
74.84%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$546.10
Upside
+ 2.49%
From current price of $532.81 to mean target of $546.10, Based on 31 analyst forecasts
Low
$376.94
Median
$561.00
High
$666.75
Price Target Revisions
1 Month
10.98%
3 Months
11.84%
Price Target Summary
31 analysts have analysed HCA and the average price target is 546.1 USD. This implies a price increase of 2.49% is expected in the next year compared to the current price of 532.81.
The average price target has been revised upward by 11.84% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
74.84%
HCA was analyzed by 31 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about HCA.
In the previous month the buy percentage consensus was at a similar level.
HCA was analyzed by 31 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-02-23 | UBS | Maintains | Buy -> Buy |
| 2026-02-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2026-02-06 | Argus Research | Maintains | Buy -> Buy |
| 2026-01-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-28 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-01-28 | UBS | Maintains | Buy -> Buy |
| 2026-01-28 | Deutsche Bank | Maintains | Buy -> Buy |
| 2026-01-28 | Keybanc | Maintains | Overweight -> Overweight |
| 2026-01-28 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-28 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-28 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-28 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-28 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-18 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-15 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2025-11-13 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-28 | Jefferies | Maintains | Buy -> Buy |
| 2025-10-27 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-27 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-27 | UBS | Maintains | Buy -> Buy |
| 2025-10-27 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-10-27 | RBC Capital | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 23, 2026
PeriodQ1 / 2026
EPS Estimate$7.27
Revenue Estimate19.275B
Revenue Q2Q5.21%
EPS Q2Q12.69%
Number of Analysts22
Next Earnings Revisions
Revenue (1 Month)
-0.31%
Revenue (3 Months)
-0.54%
EPS (1 Month)
0.92%
EPS (3 Months)
0.80%
Next Earnings Summary
HCA is expected to report earnings on 4/23/2026. The consensus EPS estimate for the next earnings is 7.27 USD and the consensus revenue estimate is 19.27B USD.
The next earnings revenue estimate has been revised downward by 0.54% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 64.968B 7.86% | 70.603B 8.67% | 75.6B 7.08% | 79.454B 5.10% | 83.381B 4.94% | 88.078B 5.63% | 93.772B 6.46% | 99.903B 6.54% | 102.844B 2.94% | 107.505B 4.53% | 112.383B 4.54% | |
| EBITDA YoY % growth | 12.704B 5.67% | 13.859B 9.09% | 15.488B 11.75% | 16.184B 4.49% | 16.944B 4.70% | 17.89B 5.58% | 18.959B 5.98% | 20.097B 6.00% | 21.027B 4.63% | 21.981B 4.54% | 22.972B 4.51% | |
| EBIT YoY % growth | 9.627B 6.34% | 10.547B 9.56% | 11.965B 13.44% | 12.441B 3.98% | 12.999B 4.49% | 13.708B 5.45% | 14.765B 7.71% | 15.722B 6.48% | 16.296B 3.65% | 17.035B 4.53% | 17.803B 4.51% | |
| Operating Margin | 14.82% | 14.94% | 15.83% | 15.66% | 15.59% | 15.56% | 15.75% | 15.74% | 15.85% | 15.85% | 15.84% | |
| EPS YoY % growth | 18.66 10.41% | 22.12 18.54% | 28.38 28.30% | 30.32 6.83% | 33.44 10.31% | 37.90 13.33% | 43.67 15.21% | 50.83 16.40% | 60.18 18.39% | 68.64 14.07% | 78.36 14.16% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 7.27 12.69% | 7.56 10.64% | 7.31 4.96% | 8.24 1.21% | 7.94 9.21% | 8.35 10.57% | 8.12 11.21% | 8.96 8.80% |
| Revenue Q2Q % growth | 19.275B 5.21% | 19.534B 4.99% | 20.07B 4.74% | 20.701B 6.09% | 20.34B 5.53% | 20.606B 5.49% | 21.129B 5.28% | 21.883B 5.71% |
| EBITDA Q2Q % growth | 3.925B 5.65% | 4.018B -14.33% | 3.894B -30.18% | 4.227B -36.92% | 4.099B 4.43% | 4.228B 5.23% | 4.174B 7.19% | 4.402B 4.14% |
| EBIT Q2Q % growth | 3B 5.08% | 3.082B 3.88% | 3.055B 3.04% | 3.329B 4.75% | 3.209B 6.97% | 3.294B 6.88% | 3.267B 6.94% | 3.457B 3.84% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.12%
EPS Next 5 Year
12.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
4.80%
Revenue Next 5 Year
5.48%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
13.98%
EBIT Next 5 Year
10.71%
HCA HEALTHCARE INC / HCA Forecast FAQ
What is the price target for HCA stock?
31 analysts have analysed HCA and the average price target is 546.1 USD. This implies a price increase of 2.49% is expected in the next year compared to the current price of 532.81.
When does HCA HEALTHCARE INC (HCA) report earnings?
HCA HEALTHCARE INC (HCA) will report earnings on 2026-04-23, before the market open.
What are the consensus estimates for HCA stock next earnings?
The consensus EPS estimate for the next earnings of HCA HEALTHCARE INC (HCA) is 7.27 USD and the consensus revenue estimate is 19.27B USD.
Can you provide the expected long term growth rate for HCA HEALTHCARE INC stock?
The expected long term growth rate for HCA HEALTHCARE INC (HCA) is 4.8%.